drugset / Trial / NCT01135511

A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease

NCT01135511

Phase 2 Completed 285 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate dose-response, efficacy and safety of CP-690,550 eye drops in patients with dry eye disease.

Timeline

Start
2010-07
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sodium Hyaluronate Other / unclassified Topical
Subject Tofacitinib Small molecule Topical

Indications